Livzon Pharma Reports No Share Capital Changes in October; Confirms Public Float Compliance

Bulletin Express
11/02

Livzon Pharmaceutical Group Inc. released its Monthly Return for Equity Issuer for the period ended 31 October 2026, showing stable share capital across both its Hong Kong–listed H shares and Shenzhen-listed A shares.

Total authorised share capital stood at 887.91 million shares, split between 299.81 million H shares and 588.10 million A shares, each with a par value of RMB 1.00. The figures were unchanged from the prior month.

Issued share volumes also remained flat. H shares in issue totalled 299.81 million, while A shares totalled 588.10 million; the company held no treasury shares in either class. Livzon Pharma confirmed that its H-share public float continues to meet the Hong Kong Stock Exchange’s 5 percent minimum requirement for PRC issuers with other listed shares.

The filing noted no activity in share options, warrants, convertible securities, or other equity instruments during the month. All statutory and regulatory obligations associated with the company’s share capital were declared satisfied by the company secretary, Liu Ning, upon submission of the report on 2 November 2026.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10